FULVESTRANT Side Effects

6764021-6 | Diarrhoea, Nausea
on Oct 05, 2009 Female patient from UNITED STATES , 74 years of age, was diagnosed with breast cancer (What is breast cancer?) and was treated with Fulvestrant (View Usage). Patient experienced the following unwanted or unexpected effects: diarrhoea, nausea (What is nausea?). Fulvestrant dosage: . During the same period patient was treated with DASATINIB (View Dasatinib Review and Dasatinib Label ), TRAZODONE HCL (View Trazodone Hcl Review and Trazodone Hcl Label ), ACETAMINOPHEN AND HYDROCODONE (View Acetaminophen And Hydrocodone Review and Acetaminophen And Hydrocodone Label ), MORPHINE (View Morphine Review and Morphine Label ), MS CONTIN (View Ms Contin Review and Ms Contin Label ), NEXIUM (View Nexium Review and Nexium Label ), COMPAZINE (View Compazine Review and Compazine Label ). Patient was hospitalized.

6601882-5 | Diarrhoea, Hyperpyrexia, Vomiting
Patient was taking Fulvestrant (View Usage). Patient had the following side effects: diarrhoea, hyperpyrexia, vomiting on Feb 17, 2010 from ITALY Additional patient health information: Female patient , weighting 123.5 lb, was diagnosed with breast cancer metastatic, depression (What is depression?), hypertension and. Fulvestrant dosage: 250 Mg On Day 1,14 And 28, Then Maintenance Dose 250 Mg Monthly. During the same period patient was treated with XANAX (View Xanax Review and Xanax Label ), ENAPREN (View Enapren Review and Enapren Label ), TENORMIN (View Tenormin Review and Tenormin Label ). Patient was hospitalized.

6532549-X | Pulmonary Embolism
Adverse event was reported on Dec 31, 2009 by a Female patient taking Fulvestrant (View Usage) (Dosage: 250 Mg Monthly Cyclic) was diagnosed with breast cancer (What is breast cancer?), hypertension, dyspepsia, abdominal discomfort, cough, hyperglycaemia and. Location: CANADA , 65 years of age, weighting 157.0 lb, After Fulvestrant was administered, patient had the following side effects: pulmonary embolism (What is pulmonary embolism?). During the same period patient was treated with EXEMESTANE (View Exemestane Review and Exemestane Label ), METOPROLOL (View Metoprolol Review and Metoprolol Label ), ZANTAC (View Zantac Review and Zantac Label ), REGLAN (View Reglan Review and Reglan Label ), ROBITUSSIN AC (View Robitussin Ac Review and Robitussin Ac Label ), MYLANTA (View Mylanta Review and Mylanta Label ), METFORMIN (View Metformin Review and Metformin Label ). Patient was hospitalized.

6337672-0 | Endometrial Cancer
on Aug 24, 2009 Female patient from UNITED STATES , 66 years of age, weighting 191.4 lb, was diagnosed with breast cancer (What is breast cancer?) and was treated with Fulvestrant (View Usage). Patient experienced the following unwanted or unexpected effects: endometrial cancer. Fulvestrant dosage: . During the same period patient was treated with ASPIRIN (View Aspirin Review and Aspirin Label ), ATIVAN (View Ativan Review and Ativan Label ), CRESTOR (View Crestor Review and Crestor Label ), HYDROCHLOROTHIAZIDE (View Hydrochlorothiazide Review and Hydrochlorothiazide Label ), OTC ANTIHISTAMINE (View Otc Antihistamine Review and Otc Antihistamine Label ), TAMOXIFEN CITRATE (View Tamoxifen Citrate Review and Tamoxifen Citrate Label ). Patient was hospitalized.


6321904-9 | Endometrial Cancer
on Aug 17, 2009 Female patient from UNITED STATES , 66 years of age, weighting 191.4 lb, was diagnosed with breast cancer (What is breast cancer?) and was treated with Fulvestrant (View Usage). Patient had the following side effects: endometrial cancer. Fulvestrant dosage: . During the same period patient was treated with ASPIRIN (View Aspirin Review and Aspirin Label ), ATIVAN (View Ativan Review and Ativan Label ), CRESTOR (View Crestor Review and Crestor Label ), HYDROCHLOROTHIAZIDE (View Hydrochlorothiazide Review and Hydrochlorothiazide Label ), OTC ANTIHISTAMINE (View Otc Antihistamine Review and Otc Antihistamine Label ). Patient was hospitalized.

6302392-5 | Hypersensitivity
Patient was taking Fulvestrant (View Usage). After Fulvestrant was administered, patient had the following side effects: hypersensitivity on Aug 07, 2009 from SPAIN Additional patient health information: Female patient , weighting 163.1 lb, was diagnosed with breast cancer (What is breast cancer?) and. Fulvestrant dosage: . During the same period patient was treated with ANASTROZOLE (View Anastrozole Review and Anastrozole Label ).

6058461-0 | Acute Myocardial Infarction, Convulsion, Depressed Level Of Consciousness, Respiratory Failure
Adverse event was reported on Jan 22, 2009 by a Female patient taking Fulvestrant (View Usage) (Dosage: 500mg D1 And 250mg D15 Of C1 Than 250mg D1 Qcycle) was diagnosed with breast cancer metastatic and. Location: UNITED STATES , weighting 123.0 lb, Patient experienced the following unwanted or unexpected effects: acute myocardial infarction, convulsion, depressed level of consciousness, respiratory failure. During the same period patient was treated with BEVACIZUMAB (10mg/kg D1 And D15) (View Bevacizumab Review and Bevacizumab Label ). Patient was hospitalized.

5586539-4 | Anorexia, Cerebral Ischaemia, Constipation, Dehydration, Hypotension, Osteomyelitis
on Jan 07, 2008 Female patient from UNITED STATES , 84 years of age, weighting 123.7 lb, was diagnosed with breast cancer (What is breast cancer?) and was treated with Fulvestrant (View Usage). Patient had the following side effects: anorexia, cerebral ischaemia, constipation (What is constipation?), dehydration, hypotension, osteomyelitis. Fulvestrant dosage: Every 28 Days. During the same period patient was treated with ANASTROZOLE (View Anastrozole Review and Anastrozole Label ), ATENOLOL (View Atenolol Review and Atenolol Label ), HYDROCHLOROTHIAZIDE (View Hydrochlorothiazide Review and Hydrochlorothiazide Label ), OXYCODONE (View Oxycodone Review and Oxycodone Label ), OXYCONTIN (View Oxycontin Review and Oxycontin Label ). Patient was hospitalized.

4655074-X | Anorexia, Asthenia, Cryptogenic Organizing Pneumonia, Diarrhoea, Dizziness Postural, Dyspnoea, Headache, Hypoxia, Pulmonary Embolism
on Apr 22, 2005 Female patient from , 64 years of age, weighting 145.5 lb, was diagnosed with breast cancer metastatic and was treated with Fulvestrant (View Usage). After Fulvestrant was administered, patient had the following side effects: anorexia, asthenia, cryptogenic organizing pneumonia, diarrhoea, dizziness postural, dyspnoea, headache (What is headache?), hypoxia, pulmonary embolism (What is pulmonary embolism?). Fulvestrant dosage: 250 Mg Q4wk Im. During the same period patient was treated with BUDESONIDE + FORMOTEROL (SYMBICORT) (View Budesonide + Formoterol (symbicort) Review and Budesonide + Formoterol (symbicort) Label ), CETRIZINE (View Cetrizine Review and Cetrizine Label ), DOCLORAZE (View Docloraze Review and Docloraze Label ), SELENIUM TRACE METAL ADDITIVE (View Selenium Trace Metal Additive Review and Selenium Trace Metal Additive Label ), CITALOPRAM (View Citalopram Review and Citalopram Label ), IMODIUM (View Imodium Review and Imodium Label ), PULMICORT (View Pulmicort Review and Pulmicort Label ). Patient was hospitalized.

4621093-2 | Anorexia, Breast Cancer Metastatic, Cryptogenic Organizing Pneumonia, Diarrhoea, Dizziness Postural, Headache, Malignant Neoplasm Progression, Metastases To Lung, Pulmonary Embolism
Patient was taking Fulvestrant (View Usage). Patient experienced the following unwanted or unexpected effects: anorexia, breast cancer metastatic, cryptogenic organizing pneumonia, diarrhoea, dizziness postural, headache (What is headache?), malignant neoplasm progression, metastases to lung, pulmonary embolism (What is pulmonary embolism?) on Mar 15, 2005 from Additional patient health information: Female patient , 64 years of age, weighting 145.5 lb, was diagnosed with breast cancer metastatic and. Fulvestrant dosage: 250 Mg Q4wk Im. During the same period patient was treated with BUDESONIDE +FORMOTEROL (SYMBICORT) (View Budesonide +formoterol (symbicort) Review and Budesonide +formoterol (symbicort) Label ), CETRIZINE (View Cetrizine Review and Cetrizine Label ), DOCLORAZE (View Docloraze Review and Docloraze Label ), SELENIUM TRACE METAL ADDITIVE (View Selenium Trace Metal Additive Review and Selenium Trace Metal Additive Label ), CITALOPRAM (View Citalopram Review and Citalopram Label ), IMODIUM (View Imodium Review and Imodium Label ), PULMICORT (View Pulmicort Review and Pulmicort Label ). Patient was hospitalized.

4595987-0 | Anorexia, Asthenia, Cryptogenic Organizing Pneumonia, Diarrhoea, Dizziness Postural, Headache, Malignant Neoplasm Progression, Pulmonary Embolism, Pyrexia
Adverse event was reported on Feb 09, 2005 by a Female patient taking Fulvestrant (View Usage) (Dosage: 250 Mg Q4wk Im) was diagnosed with breast cancer metastatic and. Location: , 64 years of age, weighting 145.5 lb, Patient had the following side effects: anorexia, asthenia, cryptogenic organizing pneumonia, diarrhoea, dizziness postural, headache (What is headache?), malignant neoplasm progression, pulmonary embolism (What is pulmonary embolism?), pyrexia. During the same period patient was treated with BUDESONIDE + FORMOTEROL (SYMBICORT) (View Budesonide + Formoterol (symbicort) Review and Budesonide + Formoterol (symbicort) Label ), CETRIZINE (View Cetrizine Review and Cetrizine Label ), DOCLORAZE (View Docloraze Review and Docloraze Label ), SELENIUM TRACE METAL ADDITIVE (View Selenium Trace Metal Additive Review and Selenium Trace Metal Additive Label ), CITALOPRAM HYDROBROMIDE (View Citalopram Hydrobromide Review and Citalopram Hydrobromide Label ), IMODIUM (View Imodium Review and Imodium Label ), PULMICORT (View Pulmicort Review and Pulmicort Label ). Patient was hospitalized.

4587290-X | Cerebral Artery Occlusion, Cerebral Infarction, Depressed Level Of Consciousness, Disease Recurrence, Dizziness, Endocarditis Noninfective, Febrile Neutropenia, Hemiplegia
on Feb 01, 2005 Female patient from , 75 years of age, weighting 117.9 lb, was diagnosed with breast cancer (What is breast cancer?) and was treated with Fulvestrant (View Usage). After Fulvestrant was administered, patient had the following side effects: cerebral artery occlusion, cerebral infarction, depressed level of consciousness, disease recurrence, dizziness (What is dizziness?), endocarditis noninfective, febrile neutropenia, hemiplegia. Fulvestrant dosage: 500 Mg Im. During the same period patient was treated with ADRIACIN (90 Mg Ivd) (View Adriacin Review and Adriacin Label ), ENDOXAN (900 Mg Ivd) (View Endoxan Review and Endoxan Label ), DECADRON (View Decadron Review and Decadron Label ), NAUZELIN (View Nauzelin Review and Nauzelin Label ), KYTRIL (View Kytril Review and Kytril Label ). Patient was hospitalized and became disabled.

4564123-9 | Cerebral Infarction, Depressed Level Of Consciousness, Disease Progression, Dizziness, Endocarditis, Febrile Neutropenia, Hemiplegia, Injection Site Pain
on Jan 13, 2005 Female patient from , 75 years of age, weighting 117.9 lb, was diagnosed with breast cancer (What is breast cancer?) and was treated with Fulvestrant (View Usage). Patient experienced the following unwanted or unexpected effects: cerebral infarction, depressed level of consciousness, disease progression, dizziness (What is dizziness?), endocarditis (What is endocarditis?), febrile neutropenia, hemiplegia, injection site pain. Fulvestrant dosage: 500 Mg Im. During the same period patient was treated with ADRIACIN (90 Mg Ivd) (View Adriacin Review and Adriacin Label ), ENDOXAN (900 Mg Ivd) (View Endoxan Review and Endoxan Label ), DECADRON (View Decadron Review and Decadron Label ), NAUZELIN (View Nauzelin Review and Nauzelin Label ), KYTRIL (View Kytril Review and Kytril Label ). Patient was hospitalized and became disabled.